HIV/AIDS
Conditions
Interventions
research group:Albuvirtide combined with Categlusevir
Sponsors
Guangzhou Eighth Peoples Hospital Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. aged between 18 and 65; 2. no gender limitation; 3. HIV antibody positive ; 4. Has been on a stable and continuous antiretroviral therapy regimen (excluding ABT) for more than 6 months, and any previous regimen or medication changes were not due to virologic failure; 5.The plasma HIV-1 RNA measurement must be less than 50 copies/mL within the 12 months prior to screening. If the measurement date is within 6 months before the screening period, the previous plasma HIV-1 RNA measurement must also be less than 50 copies/mL; 6. HIV-1 RNA<50 copies/mL in the screening test; 7. Understands and signs the informed consent form prior to any study-related procedures and agrees to comply with study requirements.
Exclusion criteria
Exclusion criteria: 1. patients allergic to CAB , ABT or the relative ingredient; 2. women who are pregnant, lactating or planning to have children; 3. patients with clinical evidence of opportunistic infection and with HIV stage III according to US CDC standard (patients with CD4+T cell count =5×ULN or ALT >=3×ULN with total bilirubin >=1.5×ULN detected during the screening period; 13. Patients with confirmed severe heart disease: myocardial infarction, congestive heart failure, documented hypertrophic cardiomyopathy, sustained ventricular tachycardia, or a personal or known family history of prolonged QT syndrome; 14. patients with tattoos or other skin diseases in the thigh area which might affect the determination of the injection sites; 15. patients with treatment of radiotherapy, cytotoxic chemotherapy drugs or any systemic immunosuppressant within 28 days; 16. patients with any unsuitable circumstances for this clinical trial according for the researcher's judgement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the ratio of failed viral supression; | — |
Secondary
| Measure | Time frame |
|---|---|
| immune cell changes; | — |
Countries
China
Contacts
Public ContactLi Linghua
Guangzhou Eighth Peoples Hospital Guangzhou Medical University
Outcome results
None listed